Company news
AIM Vaccine Co., Ltd. news in 2025
AIM Vaccine Co., Ltd.'s news releases, calls and decks from 2025, newest first.
AIM Vaccine Forecasts Surge in Stock Performance: Innovations Reinforce Leadership in Vaccine Sector
August 27, 2025
AIM Vaccine's Next-Gen mRNA Shingles Vaccine Secures Clinical Approvals in Both PRC and U.S.,mRNA Platform Advantages Shine Through
May 18, 2025
AIM's Serum-Free Iterative Rabies Vaccine Receives Acceptance for Market Registration; Institutions Predict Significant Valuation Recovery Potential for the Company
April 7, 2025
AIM Vaccine reduces losses by nearly 90% in 2024, with the iterative major product series opening up space for explosive growth in performance
March 30, 2025
AIM Vaccine's mRNA Shingles Vaccine Approved by the US FDA to Begin Clinical Trials, AI-Enabled mRNA Major Vaccine Product Development Accelerates
March 23, 2025
AIM Vaccine reported a significant reduction in losses for 2024, with several major products set to launch that are expected to drive substantial revenue growth
March 17, 2025
AIM Vaccine's Serum-Free Iterative Rabies Vaccine Has Received Production License and Will Submit for Market Registration
March 11, 2025
AIM Vaccine's Iteratively Upgraded Diploid Rabies Vaccine Approved for Clinical Trials, Showing Significantly Higher Efficacy than Marketed Diploid Rabies Vaccines
March 9, 2025
AIM Vaccine's mRNA RSV Vaccine Approved for U.S. Clinical Trials
February 26, 2025
AIM Vaccine's mRNA Shingles Vaccine Submits Clinical Application to the U.S.
February 24, 2025
AIM Vaccine Integrates DeepSeek: Innovative Technology and Growth Potential Support Valuation Upside
February 23, 2025